MENU
|
| The FNCA FY2010 Workshop on Radiation Oncology |
Report of
FNCA FY2010 Workshop on Radiation Oncology
November, 24 - 27, 2010
Chiba and Tokyo, Japan
 |
| The participants of Workshop |
The FNCA 2010 Workshop on Radiation Oncology was held from November 24 to 27, 2010, in Chiba and Tokyo, Japan. The meeting was organized by Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, in cooperation with National Institute of Radiological Sciences (NIRS) of Japan. 38 Representatives from 9 FNCA Member States, namely Bangladesh, China, Indonesia, Japan, Korea, Malaysia, the Philippines, Thailand and Vietnam, and 3 Regional Cooperation Agreement (RCA) Member States - India, Pakistan and Sri Lanka as observers and the Head of Program of Action for Cancer Therapy (PACT), both from the International Atomic Energy Agency (IAEA) participated in the workshop.
This project carried out some international joint clinical studies in order to establish common treatment protocols for uterine CERVIX cancer and nasopharyngeal cancer, which affect large numbers of people in FNCA member countries, and finally to improve the technique of radiation Oncology in the Asian region.
Opening CeremonyDr. Hirohiko TSUJII, Executive Director of NIRS, Japan opened the workshop officially with his opening address. Mr. Hiroshi KATAOKA, Director, International Nuclear and Fusion Energy Affairs Division, Research and Development Bureau of MEXT made his remarks. Following them, Mr. Massoud SAMIEI, PACT made his remarks. Dr. Sueo MACHI, FNCA Coordinator of Japan gave an Introductory Lecture in "FNCA Activities and Current Status". Dr. Takashi IMAI, Radgenomics Research Group of NIRS made a Special Lecture on, "Identification of Novel Molecular Biomarkers for Cervical Cancer Through Genomic Analysis".
 |
 |
 |
 |
 |
Dr. TUJII
(NIRS) |
Mr. KATAOKA
(MEXT) |
Mr. SAMIEI
(IAEA) |
Dr. MACHI
(FNCA) |
Dr. IMAI
(NIRS) |
Phase II Study of Chemoradiotherapy for Locally Advanced Cervical Cancer (CERVIX-III)The recent clinical data of Phase II study of concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (CERVIX-III) was presented by representatives of each participating country (China reported on 18 patients, Indonesia 5, Japan 32, Korea 10, Malaysia 14, Philippines 12, Thailand 19, and Vietnam 10). Total of 120 patients with Stage IIB (60pts) and Stage IIIB (60pts) diseases were registered and analyzed. The incidence and severity of acute toxicity were within acceptable level and most late complications were mild or moderate on the basis of the 5-year follow-up rate of 97%. The 5-year rates of grade 3-4 late rectal and bladder complications were 7.9% and 0%, respectively. The 5 year over all survival and local control rates of the patients were 55.4 % and 76.8%, respectively. CERVIX-III results were comparable or superior to those of the recognized international clinical reports. This demonstrated that the concurrent CRT was feasible and effective for patients with locally advanced cervical cancer in FNCA countries.
Phase II Study of Concurrent Chemotherapy and Extended-Field Radiotherapy for Locally Advanced Cervical Cancer (CERVIX-IV)The recent clinical data of Phase II Study of Concurrent Chemotherapy and Extended-Field Radiotherapy for Locally Advanced Cervical Cancer (CERVIX-IV) was presented by representatives of each participating country (Bangladesh reported on 13 patients, China 4, Indonesia 6, Japan 14, Korea 7, Philippines 4 , Thailand 3,). 51 patients are considered evaluable and the initial results are favorable. Recruitment of more patients is encouraged for the coming year.
Phase II Study of Chemoradiotherapy for NPC (TxN2-3) (NPC-I)The total number of enrolled patients was 121, and only 110 cases could be evaluated in the last 6 months. The recent clinical data of Phase II Study of Chemoradiotherapy for NPC (TxN2-3) (NPC-I) was presented by representatives of each participating country. (Bangladesh reported on 1 patient, China 5, Indonesia 5, Japan 0, Korea 5, Malaysia 25, Philippines 5, Thailand 5, and Vietnam 45 (In addition to the 45 from Ho Chi Minh, there were 30 enrolled patients from Hanoi which was not presented at the workshop, therefore the total number of enrolled patients from Vietnam was 75)). The PFS and OS were lower in NPC I when compared to other studies. Though T and N factors were analyzed, it was decided to look into protracted treatment time and weight loss as additional variables.
Phase II Study of Chemoradiotherapy for NPC (T3-4N0-3) (NPC-II)The recent clinical data of Phase II Study of Chemoradiotherapy for NPC (T3-4 N0-1) (NPC-II) with 65 patients was presented by representatives of each participating country. (Bangladesh reported on 0 patient, China 0, Indonesia 13, Japan 0, Korea 0, Malaysia 6, Philippines 0, Thailand 1, and Vietnam 45). 74 percent of patients completed 6 cycles of chemotherapy. Actual mean dose of cisplatin (165mg/m2) was slightly lower than Chan's study (174-187 mg/m2). Incidence of nausea, vomiting and leukopenia were lower. Toxicities were manageable with only a few patients who developed Grade IV toxicities. Clearance rate (CR) was 94 %, which was a favorable response for T3-4 disease. With a final analysis of 36 months, the overall 3-year survival rate was 83% and the 5-year overall survival is 59%.It was considered acceptable to have up to 8 cycles if the interruption was not related to toxicity. There is a need to recruit up to 100 patients.
Phase I/II Study of Chemoradiotherapy for NPC (NPC-III)The recent clinical data of Phase II Study of Chemoradiotherapy for NPC (NPC-III) was presented by representatives of each participating country. Bangladesh reported on 0, patients, China 0, Indonesia 2, Japan 0, Korea 0, Malaysia 3, Philippines 0, Thailand 0, and Vietnam 10. Regarding toxicities of concurrent chemoradiation of the protocol, regimen of chemotherapy and the number of cycles of chemotherapy, the consensus was in favor of keeping to the original protocol.
IAEA/RCA ReportReport on Outcome of RCA projects was presented by Dr. Rajiv SARIN, Tata Memorial Centre, India, and the current status of radiation oncology in Pakistan was presented by Ms. Masooma RIAZ, Gujranwala Institute of Nuclear Medicine and Radiotherapy, Pakistan, and the Current status of radiation oncology in Sri Lanka was presented by Dr. Merenchi Arachchige Yasantha ARIYARATNE, National Cancer Institute, Sri Lanka. They showed their interest to participate in future studies of FNCA.
 |
|
 |
|
 |
Dr. SARIN
(India) |
|
Ms. RIAZ
(Pakistan) |
|
Dr. ARIYARATNE
(Sri Lanka) |
QA/QC of External Beam Therapy and Future PlanThis year, measurements were done in 1 center in Bangladesh on 2 photon beams using glass dosimeter and the ionization chamber. The results were within optimum level. Future plan is to do additional audit in the new RCA participating countries - India, Pakistan and Sri Lanka. It was agreed that the next workshop will be held in China, tentatively on January 9 - 13, 2012. It was also agreed that Malaysia, Indonesia, the Philippines and Japan will be involved in discussing, drafting and writing the paper on Cervix III with 5 year follow up data for publication.
Open LectureOpen lecture to the public on "Radiation Oncology in Asia and Role of Japan" was held at Miyakezaka Hall, Shakai Bunka Kaikan as a part of the workshop and there were 10 lectures given. There were around 320 participants including general public, public office, the related persons in medical field and media representatives.
 |
|
 |
|
 |
|
 |
Mr. TOWATARI
(MEXT) |
|
Dr. YONEKURA
(NIRS) |
|
Dr. MACHI
(FNCA) |
|
Dr. YAMADA
(Tohoku Univ,) |
 |
|
 |
|
 |
|
 |
Dr. HATANO
(Chiba Cancer Center) |
|
Dr. TUJII
(NIRS) |
|
Dr. DEVI
(Malaysia) |
|
Dr. CALAGUAS
(Philippines) |
 |
|
 |
|
 |
|
 |
Dr. DANKULCHAI
(Thai) |
|
Dr. DANG
(Vietnam) |
|
Mr. SAMIEI
(IAEA) |
|
Dr. KAMADA
(NIRS) |
 |
| Open Lecture Scene |
|
Minutes of
FNCA FY2010 Workshop on Radiation Oncology
November, 24 - 27, 2010
Chiba and Tokyo, Japan
| i) Date : |
24 - 27, November, 2010 |
| ii) Venue : |
Chiba and Tokyo, JAPAN |
| iii) Host Organization : |
Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and National Institute of Radiological Sciences (NIRS) |
| iv) Participants : |
Total from 12 countries, Bangladesh, China, Indonesia, Japan, Korea, Malaysia, Philippines, Thailand, Vietnam, India, Pakistan and Sri Lanka, and IAEA (Annex 2) |
| v) Program : |
Annex 1 |
(1) Following the agreement of the 10th Forum for Nuclear Cooperation in Asia (FNCA) Coordinators Meeting in March 2010, and the 11th FNCA Meeting in November 2010, the FNCA FY2010 Workshop on Radiation Oncology was held from November 24th to 27th, 2010, in Chiba and Tokyo, Japan. The meeting was organized by Japan and the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan and in cooperation with National Institute of Radiological Sciences (NIRS) of Japan. Representatives from 9 FNCA Member States, namely Bangladesh, China, Indonesia, Japan, Korea, Malaysia, the Philippines, Thailand and Vietnam and 3 Regional Cooperation Agreement (RCA) Member States - India, Pakistan and Sri Lanka as observers and the Head of Program of Action for Cancer Therapy (PACT), both from the International Atomic Energy Agency (IAEA) participated in the workshop.
Opening Ceremony(2) Dr. Hirohiko TSUJII, Executive Director of NIRS, Japan opened the workshop officially with his opening address on behalf of the host country. He explained the objectives of the meeting and the outline of the program. He stressed the importance of this project in the framework of sciences and technologies. Mr. Hiroshi KATAOKA, Director, International Nuclear and Fusion Energy Affairs Division, Research and Development Bureau of MEXT made his remarks. Following them, Mr. Massoud SAMIEI, of PACT made his remarks.
(3) Dr. Sueo MACHI, FNCA Coordinator of Japan gave an Introductory Lecture in "FNCA Activities and Current Status". He presented the overview of FNCA activities and stressed that this Radiation Oncology Project has produced the expected outcomes so far.
(4) Dr. Takashi IMAI, Radgenomics Research Group of NIRS made a Special Lecture on, "Identification of Novel Molecular Biomarkers for Cervical Cancer Through Genomic Analysis".
(5) The agenda was adopted, and chairpersons and reporters were elected. (See Annex 1) All the participants were introduced.
Session 1: Phase II Study of Chemoradiotherapy for Locally Advanced Cervical Cancer (CERVIX-III)(6) Dr. Shingo KATO, Head, Clinical Oncology Section, Research Center Hospital for Charged Particle Therapy, NIRS introduced the protocol of CERVIX-III. The recent clinical data of Phase II study of chemoradiotherapy (CRT) for locally advanced cervical cancer (CERVIX-III) was presented by representatives of each participating country. China reported on 18, Indonesia 5, Japan 32, Korea 10, Malaysia 14, Philippines 12, Thailand 19, and Vietnam 10 patients. The summary of the follow-up data was presented by Dr. Shingo KATO. Total of 120 patients with stage IIB 60 pts and stage IIIB 60 pts were registered and analyzed. The incidence and severity of acute toxicity were within acceptable levels and most late complications were mild or moderate on the basis of the 5-year follow-up rate of 97 %. The 5-year rates of grade 3-4 late rectal and bladder complications were 7.9 % and 0 %, respectively. The 5 year over all survival and local control rates of the patients were 55.4 % and 76.8 %, respectively.
(7) CERVIX-III results were comparable or somewhat superior to those of the recognized international clinical reports. This demonstrated that the concurrent CRT was feasible and effective for patients with locally advanced cervical cancer in FNCA countries. The relationship between rectal and bladder doses and late toxicities were evaluated.
Session 2: Phase II Study of Concurrent Chemotherapy and Extended-Field Radiotherapy for Locally Advanced Cervical Cancer (CERVIX-IV)(8) Dr. Shingo KATO introduced the protocol CERVIX- IV .The recent clinical data of Phase II Study of Concurrent Chemotherapy and Extended-Field Radiotherapy for Locally Advanced Cervical Cancer (CERVIX-IV) was presented by representatives of each participating country with the following number of patients: Bangladesh 13, China 4, Indonesia 6, Japan 14, Korea 7, Philippines 4 and Thailand 3. Dr. Shingo KATO presented the summary of the clinical data. Of the total 55 patients registered from all the participating countries, 51 patients are considered evaluable. The initial results are favorable. However, the number of patients registered is still insufficient. Hence, recruitment of more patients is encouraged for the coming year.
(9) An open discussion on the clinical data of Cervix-IV followed. Some of the points raised were the higher rate of neutropenia and other non-hematologic toxicities like nausea, vomiting and bowel complication. Determinants of progression free survival (PFS) were discussed. Patients from Korea, who had chemotherapy administration not done according to the protocol, will be included in the analysis for toxicity data.
Session 3: Technical tour at NIRS(10) Dr. Yoshiharu YONEKURA, president of NIRS gave a welcome address to all the participants.
(11) The participants conducted a Technical Visit to NIRS to observe the HIMAC, PET, brachytherapy facilities and the new treatment building.
Session 4: Phase II Study of Chemoradiotherapy for NPC (any T, N2-3) (NPC-I)(12) Dr. Tatsuya OHNO, Associate Professor, Gunma University Heavy Ion Medical Center introduced the protocol NPC-I .The recent clinical data of Phase II Study of Chemoradiotherapy for NPC (any T, N2-3) (NPC-I) was presented by representatives of each participating country. The following patients were reported: Bangladesh 1, China 5, Indonesia 5, Japan 0, Korea 5, Malaysia 25, Philippines 5, Thailand 5 and Vietnam 45 patients. Dr. Tatsuya OHNO presented the summary of the clinical data and the evaluation of the FNCA NPC-I study results. He summarized the Phase II Study of Chemoradiotherapy for NPC in the last 3 years wherein 121 patients were enrolled. Only 110 cases could be evaluated at 6 months. Fifty six patients required interruption of treatment with median duration of 14 days, because of non-hematologic toxicities like mucositis, pain and dermatitis in 35 cases, 11 cases of hematologic toxicities and 13 cases for other reasons. Seventy four percent of the patients received 6 cycles of chemotherapy concurrently with radiation, 93% got at least 4 cycles and 82% had at least 2 out of 3 cycles of adjuvant chemotherapy. For the dose of 30mg/sq.m. of cisplatin used in NPC-I trial, the total dose per patient was not much different from the Chan's study. However, the toxicities were milder.
(13) An open discussion on the presented clinical data of NPC (any T, N2-3) (NPC-I) followed.
There was a discussion as the PFS and OS were lower in NPC I when compared to other studies. Though T and N factors were analyzed, it was decided to look into protracted treatment time and weight loss as additional variables.
Session 5: Phase II Study of Chemoradiotherapy for NPC (T3-4 N0-1) (NPC-II)(14) Dr. Tatsuya OHNO introduced the protocol NPC-II. The recent clinical data of Phase II Study of Chemoradiotherapy for NPC (T3-4N0-1) (NPC-II) was presented by representatives of each participating country. The following numbers were reported: Bangladesh 0, China 0, Indonesia 13, Japan 0, Korea 0, Malaysia 6, Philippines 0, Thailand 1, and Vietnam 45. Dr. Tatsuya OHNO presented the summary of the clinical data of 70 cases and the evaluation of the FNCA NPC-II study results. Seventy-four percent 74% of patients completed 6 cycles of chemotherapy. Actual mean dose of cisplatin 165mg / m2 was slightly lower than Chan's study 174-187 mg/m2. Incidence of nausea, vomiting and leukopenia were also lower. Toxicities were manageable with only few patients developing grade IV toxicities. Clearance rate CR was 94%, which was a favorable response for T3-4 disease. With a final analysis of 36 months of the phase II, the 3 years overall survival rate is 83% and the 5 years overall survival is 59%.
(15) An open discussion on the clinical data of NPC (T3-4, N0-1) (NPC-II) followed.
Impact of diet and nutrition on treatment outcome was discussed, with feedback given by participants. The question of whether to accept the chemo cycles more than 6 due to treatment interruption was discussed. It was considered acceptable to have up to eight cycles if the interruption was not related to toxicity. There is a need to recruit up to 100 patients.
Session 6: Phase I/II Study of Chemoradiotherapy for NPC (NPC-III)(16) Dr. Tatsuya OHNO introduced the protocol NPC-III. The recent clinical data of Phase II Study of Chemoradiotherapy for NPC (NPC-III) was presented by representatives of each participating country. Bangladesh reported on 0, patients, China 0, Indonesia 2, Japan 0, Korea 0, Malaysia 3, Philippines 0, Thailand 0, and Vietnam 10. Dr. OHNO presented the summary of the clinical data and the evaluation of the FNCA NPC-III study results.
(17) Open discussion on the clinical data of Phase I/II study of chemoradiotherapy for NPC-III followed. A discussion was made regarding toxicities of concurrent chemoradiation of the protocol, regimen of chemotherapy and the number of cycles of chemotherapy. Consensus was in favor of keeping to the original protocol.
Session 7: IAEA/RCA Report(18) Report on Outcome of RCA projects, was presented by Dr. Rajiv SARIN, Director of Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Department of Radiation Oncology, Tata Memorial Centre, India. The current status of radiation oncology in Pakistan was presented by Ms. Masooma RIAZ, Deputy Chief Scientist, Gujranwala Institute of Nuclear Medicine and Radiotherapy, Pakistan. The Current status of radiation oncology in Sri Lanka was presented by Dr. Merenchi Arachchige Yasantha ARIYARATNE, Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka.
These RCA member states demonstrated their capabilities in terms of patient resources, technical resources and expertise to contribute to clinical studies similar to the ones conducted by FNCA. They showed their interest to participate in future studies of FNCA.
Session 8: QA/QC of External Beam Therapy and Future Plan(19) Report on a summary of intercomparison measurements using validated glass dosimeters done at 9 centers were presented by Dr. Hideyuki MIZUNO. This year, measurements were done in 1 center in Bangladesh on 2 photon beams using glass dosimeter and the ionization chamber. The results were within optimum level.
Future plan is to do additional audit in the new RCA participating countries - India, Pakistan and Sri Lanka.
(20) Regarding Next Workshop, Schedule of the Next Workshop and Other activities, the following items were discussed and agreed.
1: We agreed that the next workshop will be held in China, tentatively on January 9 - 13, 2012.
2: It was agreed that Malaysia, Indonesia, the Philippines and Japan will be involved in discussing,
drafting and writing the paper on Cervix III with 5 year follow up data for publication.
3: It was emphasized that there is a need to disseminate the results of FNCA studies at national
and international meetings through lectures, poster presentation, panel discussion etc.
Session 9: Drafting the Workshop Minutes(21) The draft minutes presented by reporters were discussed, amended. The minutes were unanimously adopted by the workshop participants.
Closing Session(22) Dr. Hirohiko TSUJII closed the workshop officially with his closing remark, in which he expressed his appreciation to the participants as well as his expectations for the future of the project. Participants expressed appreciation to the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan and National Institute of Radiological Sciences (NIRS) for the excellent conduct of the Workshop and for their hospitality.
Session 10: Technical Visit at Komagome Hospital(23) The participants conducted a Technical Visit to Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital and had lectures on Stereotactic Body radiotherapy (SBRT) and 3-dimensional conformal radiotherapy (3DCRT) for solitary lung tumors, Low dose rate brachytherapy (LDRBT) for localized prostate cancer, Intraoperative Radiation Therapy (IORT) for pancreatic cancers and spinal metastases, and Hyperthermia for soft tissue sarcoma (STS) and malignant pleural mesothelioma (MPM), and observed the irradiation chamber.
Session 11: Open Lecture(24) Open lecture to the public was held at Miyakezaka Hall, Shakai Bunka Kaikan as a part of the workshop. There were around 320 participants including general public, public office, the related persons in medical field and media representatives. In Opening Ceremony, Mr. Hayashi TOWATARI, MEXT and Dr. Yoshiharu YONEKURA, NIRS made welcome remarks. Dr. Sueo MACHI gave an opening lecture "FNCA activities for sustainable development in Asia".
(25) On the theme of High-tech radiation therapy in Japan, Dr. Shogo YAMADA, President of Tohoku University Hospital Cancer Center gave a lecture "Radiotherapy Today in Japan" and Dr. Kazuo HATANO, Director of Department of Radiation Oncology, Chiba Cancer Center gave a lecture "Intensity Modulated Radiation Therapy (IMRT)".
(26) On the theme of Radiation therapy in Asia, Dr. Hirohiko TSUJII and the representatives from Asian countries; Dr. C.R. Beena DEVI, Malaysia, Dr. Miriam Joy C. CALAGUAS, the Philippines, Dr. Pittaya DANKULCHAI, Thailand and Dang Huy Quoc THINH, Vietnam made presentations on "FNCA radiation oncology project in Asia". Mr. Massoud SAMIEI, PACT/IAEA gave a lecture on "IAEA/PACT: Building Self-Sustaining Cancer Control Capacity and Infrastructure in Asia & Pacific Region Using Radiation medicine as the Anchor".
(27) As Special Lecture, Dr. Tadashi KAMADA, Head of The Research Center for Charged Particle Therapy, NIRS gave his lecture on Heavy Ion Radiotherapy.
(28) Dr. Hirohiko TSUJII concluded the Open Lecture with his closing remarks.
|
Program of
FNCA FY2010 Workshop on Radiation Oncology
November, 24 - 27, 2010
Chiba and Tokyo, Japan
Date: November, 24 - 27, 2010
Venue & Stay: Mitsui Garden Hotel Chiba
Day 1, Wed, 24 November 2010
| 08:30-09:00 |
Registration |
09:00-10:00
09:00-09:03
09:03-09:06
09:06-09:09
09:09-09:25
09:25-09:55
09:55-09:58
09:58-10:00
|
Opening Ceremony
Opening Address
Hirohiko Tsujii(Japan),Project Leader
Opening Remark
Ministry of Education, Culture, Science, Sports, Science and Technology
(MEXT)
Remark
Massoud Samiei, PACT (IAEA)
Introductory Lecture:
FNCA Activities and Current Status
Sueo Machi, FNCA Coordinator of Japan
Special Lecture:
Identification of Novel Molecular Biomarkers for Cervical Cancer through
Genomic Analysis
Takashi Imai, Radgenomics Research Group, NIRS
Adoption of the Agenda
Group Photography
|
| 10:00-10:15 |
Coffee Break |
| 10:15-12:00 |
Session 1: Phase II Study of Chemoradiotherapy for Locally Advanced Cervical Cancer (CERVIX-III)
Co-chairs:
Pittaya Dankulchai (Thailand)
Nana Supriana (Indonesia)
1) Introduction of the Protocol
Shingo Kato (Japan)
2) Presentation on the follow-up data from each country
China
Indonesia
Japan
Korea
Malaysia
The Philippines
Thailand
Viet Nam
3) Summary of the follow-up data
Shingo Kato (Japan)
4) Discussion
|
| 12:00-13:00 |
Lunch |
| 13:00-15:00 |
Session 2: Phase II Study of Concurrent Chemotherapy and Extended-Field Radiotherapy for Locally Advanced Cervical Cancer (CERVIX-IV)
Co-chairs:
Rey H. de los Reyes (the Philippines)
Takashi Nakano (Japan)
1) Introduction of the Protocol
Shingo Kato (Japan)
2) Presentation on the clinical data from each country
Bangladesh
China
Indonesia
Japan
Korea
The Philippines
Thailand
3) Summary of the clinical data
Shingo Kato (Japan)
4) Discussion
|
| 15:00-15:15 |
Coffee Break |
15:15-18:00
15:15-16:00
16:00-16:10
16:10-18:00
|
Session 3: Technical tour to NIRS
move to NIRS
Welcome Remark
Yoshiharu Yonekura, President of NIRS
Technical tour to NIRSs: HIMAC & PET facilities & RALS & New treatment room
NIRS
|
Day 2, Thu, 25 November 2010
| 09:00-12:00 |
Session 4: Phase II Study of Chemoradiotherapy for NPC (any T N2-3) (NPC-I)
Co-chairs:
Yaowarak Chansilpa (Thailand)
Dang Huy Quoc Thinh (Viet Nam)
1) Introduction of the Protocol
Tatsuya Ohno (Japan)
2) Presentation on the clinical data from each country
Bangladesh
China
Indonesia
Korea
Malaysia
The Philippines
Thailand
Viet Nam
3) Summary of the clinical data
Tatsuya Ohno (Japan)
4) Discussion
|
| 10:30-10:50 |
Coffee Break |
| 10:50-12:00 |
5) Evaluation of treatment results
Tatsuya Ohno (Japan)
|
| 12:00-13:00 |
Lunch |
| 13:00-15:00 |
Session 5: Phase II Study of Chemoradiotherapy for NPC (T3-4 N0-1) (NPC-II)
Co-chairs:
Beena C.R Devi (Malaysia)
Dyan Erawati (Indonesia)
1) Introduction of the Protocol
Tatsuya Ohno (Japan)
2) Presentation on the clinical data from each country
Indonesia
Malaysia
Thailand
Viet Nam
3) Summary of the clinical data
Tatsuya Ohno (Japan)
4) Discussion
|
| 15:00-15:30 |
Coffee Break |
| 15:30-17:00 |
Session 6: Phase II Study of Chemoradiotherapy for NPC (NPC-III)
Co-chairs:
Chul-Koo Cho (Korea)
Parvin A. Banu (Bangladesh)
1) Introduction of the Protocol
Tatsuya Ohno (Japan)
2) Presentation on the clinical data from each country
Indonesia
Malaysia
Viet Nam
3) Summary of the clinical data
Tatsuya Ohno (Japan)
4) Discussion
|
| 17:00-18:00 |
Session 7: IAEA/RCA Report
Chair:
Hirohiko Tsujii (Japan)
1) Outcome of RCA projects
Rajiv Sarin (India)
2) Current Status of radiation oncology in Pakistan
Masooma Riaz (Pakistan)
3) Current Status of radiation oncology in Pakistan
Merenchi A.Yasantha Ariyaratne (Sri Lanka)
4) Discussion
|
Day 3, Fri, 26 November 2010
09:00-10:30
09:00-09:30
09:30-10:30
|
Session 8: QA/QC of External Beam Therapy, Future plan,
Other activities
Co-chairs:
Cao Janping (China)
Tang Tieng Swee (Malaysia)
QA/QC of External beam therapy, Report of the Fieldwork
Hideyuki Mizuno (Japan)
Next Workshop, Schedule of the next Workshop, Other activities
|
| 10:30-10:45 |
Coffee Break |
| 10:45-11:45 |
Session9: Drafting the Workshop Minutes
Co-chairs:
Miriam Joy C. Calaguas (Philippines)
Beena Devi (Malaysia)
Tang Tieng Swee(Malaysia)
1) Discussion
2) Adoption of the Minutes
|
| 11:45-12:00 |
Closing Session
Closing Remark
Hirohiko Tsujii (Japan), Project Leader
|
| 12:00-13:00 |
Lunch |
13:30-15:00
15:00-16:00
17:00-18:30
|
Move to Tokyo
Session 10: Technical Visit at Tokyo Metropolitan Cancer and
Infectious Diseases Center Komagome Hospital
Move to Fujiya Hotel Yaesu
|
Day 4, Sat, 27 November 2010
| 08:40-09:10 |
Move to Syakaibunkakaikan Miyakezaka hall |
09:00-13:00
09:00-09:30
09:30-09:45
09:45-10:05
|
Session 11: Open Lecture
Registration
Opening Ceremony
Welcome Remark
MEXT
Welcome Remark
Yoshiharu Yonekura, President of NIRS
Nuclear Technology Contributing Sustainable Development of Asia:
FNCA Success Story
Sueo Machi (FNCA Coordinator of Japan)
|
10:05-10:25
10:25-10:45
|
I. High-tech radiation therapy in Japan
Current status of radiation oncology in Japan
Shogo Yamada (Tohoku University Hospital Cancer Center)
Intensity Modulated Radiation Therapy (IMRT)
Kazuo Hatano (Chiba Cancer Center)
|
| 10:45-11:00 |
Break |
11:00-12:00
12:00-12:20
|
II. Radiation therapy in Asia
FNCA radiation oncology project in Asia
Hirohiko Tsujii (FNCAProject Leader)
Beena C.R Devi (Malaysia)
Miriam Joy C. Calaguas (the Philippines)
Pittaya Dankulchai (Thailand)
Dang Huy Quoc Thinh (VietNam)
IAEA/PACT: Building Self-Sustaining Cancer Control Capacity and Infrastructure in Asia & Pacific Region Using Radiation Medicine as the Anchor
Massoud Samiei, PACT (IAEA)
|
12:20-12:45
12:45-12:50
|
III. Special Lecture
Carbon ion radiotherapy, what are the differences?
Tadashi Kamada (NIRS)
Closing Session
Closing Remark
Hirohiko Tsujii (Japan), Project Leader
|
|
List of Participants
FNCA FY2010 Workshop on Radiation Oncology
November, 24 - 27, 2010
Chiba and Tokyo, Japan
Bangladesh
Dr. Parvin Akhter BANU
Senior Consultant,
Delta Hospital Ltd.
Dr. Boachu Kumar BOSE *
Principal Medical Officer / Director,
Center for Nuclear Medicine & Ultrasound,
Bangladesh Atomic Energy Commission (BAEC)
China
Prof. CAO Jianping (Project Leader)
Director,
School of Radiation Medicine & Public Health,
Soochow University
Dr. XU Xiaoting *
Associate Chief Physician,
The First Affiliated Hospital of Soochow University
Indonesia
Dr. SUPRIANA Nana (Project Leader)
Medical Staff,
Radiotherapy Department, Cipto Mangunkusumo Hospital
Dr. Dyah Erawati *
Head,
Radiotherapy Division, Dr. Soetomo General Hospital
Japan
Dr. Hirohiko TSUJII (Project Leader)
Executive Director
National Institute of Radiological Sciences (NIRS)
Dr. Shingo KATO
Head,
Clinical Oncology Section Research Center Hospital for Charged Particle Therapy,
National Institute of Radiological Sciences (NIRS)
Dr. Kunihiko KOBAYASHI
Professor,
Department of Respiratory Med.
International Medical Center, Saitama Medical University
Dr. Shogo YAMADA
President of Cancer Center,
Professor and Chairman of Department of Radiation Oncology,
Tohoku University Hospital
Dr. Takashi NAKANO
Director,
Gunma University Heavy Ion Medical Research Center
Professor & Chairman, Department of Radiation Oncology,
Gunma University, Graduate School of Medicine
Dr. Tatsuya OHNO
Associate Professor,
Gunma University Heavy Ion Medical Center
Dr. Yoshiharu YONEKURA
President,
National Institute of Radiological Sciences (NIRS)
Dr. Takashi IMAI
Radgenomics Research Group,
National Institute of Radiological Sciences (NIRS)
Dr. Hideyuki MIZUNO
Researcher (Medical Physicist),
National Institute of Radiological Sciences (NIRS)
Mr. Hiroshi KATAOKA
Director,
International Nuclear and Fusion Energy Affairs Division,
Research and Development Bureau,
Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan
Mr. Takeshi ISHIZAKA
Special Staff,
International Nuclear and Fusion Energy Affairs Division,
Research and Development Bureau,
Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan
Mr. Sentaro TOIDA
Administrative Researcher,
International Nuclear and Fusion Energy Affairs Division,
Research and Development Bureau,
Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan
Dr. Sueo MACHI (Coordinator)
FNCA Coordinator of Japan
Korea
Dr. Chul Koo CHO * (Project Leader)
Head,
Department of Radiation Oncology,
Korea Institute of Radiological & Medical Sciences (KIRAMS),
Korea Cancer Center Hospital (KCCH)
Dr. Keum Bae KIM *
Senior Researcher,
Medical PhysicistKorea Institute of Radiological & Medical Sciences (KIRAMS),
Korea Cancer Center Hospital (KCCH)
Malaysia
Dr. TANG Tieng Swee (Project Leader)
Senior Medical Physicist,
Department of Radiotherapy & Oncology,
Sarawak General Hospital
Dr. DEVI Beena *
Senior Consultant Clinical Oncologist,
Department of Radiotherapy,
Oncology & Palliative Care,
Sarawak General Hospital
Philippines
Dr. CALAGUAS, Miriam Joy C. (Project Leader)
Medical Specialist III,
Jose R. Reyes Medical Center
Chairperson,
Dept. of Radiation Oncology,
St. Luke's Medical Center, Philippines
Dr. DE LOS REYES, Rey H. *
Associate Professor and Chairman,
Department of Obstetrics and Gynecology,
Far Eastern University - Dr. Nicanor ReyesMedical Foundation (FEU-NRMF)
Medical Specialist III/ Gynecologic Oncologist,
Jose R. Reyes Memorial Medical Center(JRRMMC)
Thailand
Dr. Yaowalak CHANSILPA (Project Leader)
Associate Professor,
Division of Radiation Oncology,
Department of Radiology, Faculty of Medicine Siriraj Hospital,
Mahidol University
Dr. Pittaya DANKULCHAI *
Radiation Oncologist
Division of Radiation Oncology,
Department of Radiology, Faculty of Medicine Siriraj Hospital,
Mahidol University
Vietnam
Dr. DANG Huy Quoc Thinh *
Vice Director,
Ho Chi Minh City Oncology Hospital
Dr. TO Anh Dung
Vice-Head of Department,
National Cancer Hospital (K Hospital)
IAEA PACT
Mr. Massoud SAMIEI *
Head,
Program of Action for Cancer Therapy (PACT),
International Atomic Energy Agency (IAEA)
India (RCA)
Dr. Rajiv SARIN *
Director,
Advanced Centre for Treatment,
Research and Education in Cancer (ACTREC),
Department of Radiation Oncology,
Tata Memorial Centre
Pakistan (RCA)
Ms. Masooma RIAZ *
Deputy Chief Scientist,
Gujranwala Institute of Nuclear Medicine and Radiotherapy,
Pakistan Atomic Energy Commission (PAEC)
Sri Lanka (RCA)
Mr. Merenchi A. Yasantha ARIYARATNE *
Consultant Clinical Oncologist,
National Cancer Institute, Maharagama, Sri Lanka
Japan (Secretariat)
Ms. Tomoko TAKAHASHI
Hospital, Research Center for Charged Particle Therapy,
National Institute of Radiological Sciences (NIRS)
Ms. Kaori YAMADA
National Institute of Radiological Sciences (NIRS)
Ms. Atsuko TAKANO
Section Head, International Affairs and Research Department,
Nuclear Safety Research Association (NSRA)
Ms. Ai YAMADA
International Affairs and Research Department,
Nuclear Safety Research Association (NSRA)
*Participants with non-FNCA budget
|
|
|
